Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab +/- Tremelimumab in Pediatric Advanced Solid Tumors and Hematological Malignancies
NCT03837899Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2019
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 7
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in pediatric cancer, solid tumor, hematological malignancy, non-Hodgkin lymphoma (NHL), sponsored by AstraZeneca. Started Mar 2019; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
pediatric cancersolid tumorhematological malignancynon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03837899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837899.